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Cutaneous melanoma is the most aggressive form of skin cancer. This aggressive-
ness appears to be due to the cancer cells’ ability to reversibly switch between
phenotypes with non-invasive and invasive potential, and microphthalmia-asso-
ciated transcription factor (MITF) is known to play a central role in this process.
The transcription factor glioma-associated oncogene homolog 1 (GLI1) is a com-
ponent of the canonical and noncanonical sonic hedgehog pathways. Although
GLI1 has been suggested to be involved in melanoma progression, its precise role
and the mechanism underlying invasion remain unclear. Here we investigated
whether and how GLI1 is involved in the invasive ability of melanoma cells. Gli1
knockdown (KD) melanoma cell lines, established by using Gli1-targeting lentivi-
ral short hairpin RNA, exhibited a markedly reduced invasion ability, but their
MITF expression and activity were the same as controls. Gli1 KD melanoma cells
also led to less lung metastasis in mice compared with control melanoma cells.
Furthermore, the Gli1 KD melanoma cells underwent a mesenchymal-to-epithe-
lial-like transition, accompanied by downregulation of the epithelial-to-mesench-
ymal transition (EMT)-inducing transcription factors (EMT-TF) Snail1, Zeb1 and
Twist1, but not Snail2 or Zeb2. Collectively, these results indicate that GLI1 is
important for maintaining the invasive and mesenchymal-like properties of mela-
noma cells independent of MITF, most likely by modulating a subset of EMT-TF.
Our findings provide new insight into how heterogeneity and plasticity are
achieved and regulated in melanoma.
M alignant melanoma represents a small percentage of skincancers, but is the major cause of death from these can-
cers.(1,2) Melanoma arises from melanocytes (pigment cells),
and approximately 50% of melanomas harbor the activating
BRAFV600E mutation.(3) Although small molecule inhibitors
targeting BRAF and MEK, a downstream effector of BRAF,
are effective in BRAF-mutated melanoma, virtually all of the
tumors develop resistance to the drugs, usually within a few
months.(4–10) Immune checkpoint inhibitors, such as an anti-
programmed death 1 (PD-1) antibody, provide durable
responses in patients with metastatic melanoma independent of
the BRAF mutational status; however, a significant proportion
of patients either do not respond or develop resistance to the
PD-1 immunotherapy.(11–15)
Tumor heterogeneity poses a major challenge for the effec-
tive treatment of cancer. Accumulating evidence indicates that
the heterogeneity in melanoma can be driven through pheno-
typic plasticity.(16–18) That is, the aggressiveness of melanoma
appears to be due to the cancer cells’ ability to reversibly
switch between different phenotypes with non-invasive and
invasive potential. Microphthalmia-associated transcription fac-
tor (MITF) plays an essential role in determining the melano-
cyte lineage and has been proposed to act as a rheostat for the
cellular heterogeneity in melanoma.(17,19,20) In the rheostat
model, low levels of MITF generate invasive, stem-like cells,
whereas high MITF levels stimulate proliferation and inhibit
invasion. Epithelial-to-mesenchymal transition (EMT) is a
dynamic and reversible phenotypic switching process where
polarized epithelial cells transition to motile mesenchymal
cells; this process is essential for normal development and is
widely thought to be a critical switch for tumor-cell invasive-
ness.(21–23) EMT is driven by an interconnected signaling net-
work of EMT-inducing transcription factors (EMT-TF),
including SNAIL, TWIST and ZEB. Recent studies have
shown that some EMT-TF play important roles in malignant
melanoma, but their regulation and function are different from
those in epithelial cancers.(24,25) These studies also suggest that
the EMT-TF SNAIL2 and ZEB2 act as tumor-suppressor pro-
teins by activating an MTIF-dependent melanocyte differentia-
tion program.
Sonic hedgehog (Shh) signaling has critical roles in embry-
onic patterning, and aberrant Shh-signaling activation is impli-
cated in various cancer types, including skin cancer.(26–29) The
Shh signal is transduced by a receptor complex composed of
two proteins, Patched (PTCH) and Smoothened (SMO). The
binding of Shh to PTCH relieves PTCH’s repression of SMO.
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The transcription factor glioma-associated oncogene homolog
1 (GLI1) acts as a terminal, positive effector of Shh signaling,
and Gli1 itself is a Shh-target gene. GLI1’s expression and
activity are also regulated through a non-canonical Shh path-
way, such as those involving hypoxia or transforming growth
factor (TGF)-b.(30–32) GLI1 has been suggested to be involved
in melanoma progression, although its precise role and the
mechanism underlying invasion remain unclear. In this study,
we show that GLI1 has a role in maintaining the invasive and
mesenchymal-like properties of melanoma cells.
Materials and Methods
Cell culture. B16F10 murine melanoma cells were obtained
from Riken BioResource (Tokyo, Japan), and MeWo and
G361 human melanoma cells from JCRB Cell Bank (Osaka,
Japan). B16F10 cells were cultured in RPMI 1640 medium
(Nissui Pharmaceutical, Tokyo, Japan) supplemented with 10%
FBS, and MeWo and G361 cells in Eagle’s Minimum Essen-
tial Medium (EMEM) with non-essential amino acids (Wako,
Tokyo, Japan) and 10% FBS. To prepare conditioned medium,
NIH3T3 cells, a kind gift from Dr Chiaki Takahashi (Kana-
zawa University, Kanazawa, Japan), were cultured in RPMI
1640 (Nissui Pharmaceutical) supplemented with 10% FBS.
Mouse embryonic fibroblasts (MEF) and HEK293T cells were
cultured as described previously.(33) In some experiments,
cyclopamine (LKT Labs, St. Paul, MN, USA) and forskolin
(Wako) were DMSO and added to the culture medium (see
Figs 1 and S1).
Plasmids, viral vector preparation, and viral infection. The
pLVTH lentivirus plasmid vectors for shRNA were constructed
as previously described.(34) In pLVTH, enhanced green fluores-
cent protein (EGFP) is encoded as a marker. Previously
reported target sequences, which are listed in Table S1, were
used to express shRNA against mouse Gli1, human Gli1 and
firefly Luciferase (Luc). Lentiviral vectors were produced as
previously described.(34) B16F10, MeWo and G361 cells were
infected with the lentiviruses, and were analyzed at 7 days
post-infection (dpi). The mammalian expression plasmid
pCL20c-CMV-EGFP was described previously.(34) The coding
regions of full-length mouse GLI1 with hemagglutinin (HA)
tag sequences at the 50 and 30 ends were inserted into pCL20c-
CMV(34) to generate pCL20c-CMV-HA-GLI1 and pCL20c-
CMV-GLI1-HA, respectively. The potential promoter regions
of Snail1, Zeb1 and Twist1 were obtained by PCR using
B16F10 genomic DNA as templates. The PCR products were
subcloned into a promoterless pGL3 vector (Promega, Madi-
son, WI, USA). All PCR products were verified by sequenc-
ing.
Western blot analysis. Total cell lysates were prepared and
analyzed by western blotting as previously described,(34) using
rabbit anti-GLI1 H300 (sc-20687), rabbit anti-E-cadherin H108
(sc-7870; each diluted to 1:1000; Santa Cruz Biotechnology,
Santa Cruz, CA, USA), rabbit anti-MITF N2C1 (1:1000;
GTX113776; GeneTex, Irvine, CA, USA), and mouse anti-a-
tubulin (1:3000; #T5168; Sigma-Aldrich, St. Louis, MO, USA)
antibodies (Abs).
Quantitative reverse-transcription PCR. Total RNA was pre-
pared and qRT-PCR was performed as previously
described.(35) Primers used for qRT-PCR are listed in
Table S2.
Phalloidin staining and immunocytochemistry. Phalloidin
staining was carried out as described previously.(36) Immuno-
cytochemistry was performed following standard protocols as
previously described,(34) using the rabbit anti-E-cadherin H108
(1:200; Santa Cruz Biotechnology) Ab. The secondary Ab was
goat Alexa fluor 568-conjugated anti-rabbit IgG Ab (1:1000;
Thermo Fisher Scientific, Waltham, MA, USA). Nuclei were
stained with DAPI (Sigma-Aldrich). Fluorescent images were
captured using a confocal laser scanning microscope (LSM510
META, Carl Zeiss, Oberkochen, Germany) with a 209 or 409
objective lens. In some experiments (Fig. 4d), 12 Z-stack
images at 1.2-lm intervals were acquired using the confocal
microscope with a 409 objective lens.
Luc assay. To measure the GLI-mediated transcriptional
repression in response to cyclopamine, B16F10 cells were pla-
ted in 12-well plates at 8 9 104 cells per well, and were
cotransfected with 950 ng of the Luc reporter vector (8xGLI-
BS-Luc or 8xmGli-BS-Luc, kind gifts from Dr Hiroshi Sasaki,
Kumamoto University, Kumamoto, Japan)(37) and 50 ng of the
Renilla Luc control vector (pRL-TK-Luc, Promega) using
Lipofectamine LTX with Plus reagent (Thermo Fisher Scien-
tific). Six hours after transfection, the medium was changed,
and the cells were treated with either vehicle (DMSO) or
cyclopamine for 24 h. The cells were then lysed, and the Luc
activity was measured as previously described.(34) To examine
the effect of GLI1 overexpression on the potential promoters
of Snail1, Zeb1 and Twist1, 350 ng of the Luc reporter vector
containing the potential promoter region, 140 ng of either
pCL20c-CMV-EGFP or pCL20c-CMV-HA-GLI1, and 10 ng
of pRL-TK-Luc were cotransfected into HEK293T cells plated
in 12-well plates at 2 9 105 cells per well. Thirty-six hours
after transfection, the cells were lysed, and subjected to Luc
assays as described previously.(34)
Matrigel invasion assay. The cell invasion assay was carried
out using Transwell chambers with inserts of an 8-lm pore
size (Corning, Corning, NY, USA). The upper chamber was
pre-coated with Matrigel (300 lg/mL, 100 lL per well for
B16F10 cells; 200 lg/mL, 100 lL per well for MeWo cells,
BD Biosciences, San Jose, CA, USA). NIH3T3-conditioned
medium containing 10% FBS (for B16F10 cells) or EMEM
complete growth medium supplemented with 10% FBS (for
MeWo and G361 cells) was added to the lower chamber,
which was pre-coated with 50 lL of fibronectin (50 lg/mL;
Thermo Fisher Scientific), and then 1 9 105 cells were seeded
on the upper chamber in serum-free medium containing 0.1%
BSA. In some experiments (Fig. 1), cyclopamine was added to
both the upper and lower chambers. At 24 h (for B16F10
cells) or 30 h (for MeWo and G361 cells) after seeding, the
cells were fixed in 4% paraformaldehyde and stained with
0.1% crystal violet. Cells remaining on the upper side of the
inserts were scraped with cotton swabs, and cells on the lower
side were counted.
Cell migration assay. To measure the cell migration activity,
wound-healing (for B16F10 cells) and Transwell chamber (for
MeWo and G361 cells) assays were performed. B16F10 cells
were replated at a saturation density (2 9 105 cells per well of
a 12-well plate) in RPMI 1640 supplemented with 1% FBS,
and incubated for 6 h. The plates were then scratched manu-
ally with a sterile pipette tip. After being washed with RPMI
1640, the wounded regions were allowed to heal for 12 h in
RPMI 1640 medium supplemented with 1% FBS. The cell
movements were monitored using a cultured cell monitoring
system (CCM-1.4XYZ/CO2, Astec, Fukuoka, Japan). Video
images were collected at 15-min intervals for 12 h. Transwell
chamber migration assays were carried out as described
above (Matrigel invasion assay) without pre-coating the upper
chamber.
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Fig. 1. Blockade of Shh signaling inhibits the invasion activity of melanoma cells. (a) B16F10 cells were cotransfected with a firefly Luc reporter
plasmid containing GLI-binding sites (8xGli-BS-Luc) or mutated sites (8xmGli-BS-Luc) together with a Renilla Luc reporter plasmid, and were
assayed for Luc activity, as described in the Materials and Methods. (b,c) B16F10 cells were treated with cyclopamine for 48 h, and were sub-
jected to western blotting using anti-GLI1, anti-GLI2, anti-MITF (b) and anti-GLI3 (c) Abs. Lane 1, cell lysate prepared from mouse embryonic
fibroblasts (MEF). a-tubulin, a loading control. (d) B16F10 cells were pre-treated with cyclopamine for 24 h, and were subjected to a Matrigel
invasion assay. Representative images captured using a microscope (BX50, Olympus, Tokyo, Japan) are shown. (e) Quantification of the results in
(d). The average numbers of invading cells from five randomly chosen fields acquired using a 209 objective lens are shown. (f,g) B16F10 cells
were untreated or treated with cyclopamine for 48 h, and the relative mRNA levels of Mitf (f) and Tyr (g) were then measured by quantitative
RT-PCR. The expression levels were normalized to Gapdh. Quantitative data are expressed as the mean  SEM of three independent experi-
ments. *P < 0.05; **P < 0.01; ***P < 0.001; n.s., not significant; Cyc, cyclopamine; NT, untreated.
© 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
on behalf of Japanese Cancer Association.
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MTT assay. The MTT assay was used to examine cell viabil-
ity. B16F10, MeWo or G361 cells were seeded in 24-well
plates (8 9 104 cells per well), and incubated overnight. The
medium was then changed to serum-free medium containing
0.1% BSA, and the cells were incubated for 24 h to mimic the
Matrigel invasion assay described above. In some experiments
(Fig. S1), cyclopamine was added to the culture medium. The
cells were washed with PBS and incubated with MTT solution
(0.5 mg/mL, Sigma) for 1 h. The resulting insoluble formazan
was dissolved in 0.04 N HCl in isopropanol, and the absor-
bance at 595 nm was measured.
ChIP assays. ChIP assays were performed essentially as
described previously.(38) B16F10 cells were cross-linked with
formaldehyde, lysed, and sonicated using a Bioruptor
Fig. 2. Gli1 knockdown (KD) inhibits the invasion and migration abilities of melanoma cells. (a) B16F10 cells were infected with lentiviral shLuc,
shGli1-1 or shGli1-2 (termed B16F10_shLuc, B16F10_shGli1-1 and B16F10_shGli1-2 cells, respectively), and the protein levels of GLI1 and MITF were
examined by western blotting using anti-GLI1 and anti-MITF Abs. a-tubulin, a loading control. (b) Matrigel invasion assays were performed as in
Figure 1d, using B16F10_shLuc, B16F10_shGli1-1 and B16F10_shGli1-2 cells. Representative images of invading cells are shown. (c) Quantification
of the results in (b), performed as described in Figure 1e. (d) B16F10_shLuc, B16F10_shGli1-1 and B16F10_shGli1-2 cells were analyzed by in vitro
wound-healing assays. Phase-contrast time-lapse images at 0, 3, 6 and 9 h are shown. Curved black lines indicate the boundary between the
unscratched and scratched areas. (e) Quantification of wound size using ImageJ software (NIH). (f,g) Relative mRNA levels of Mitf (f) and Tyr (g)
in B16F10_shLuc, B16F10_shGli1-1 and B16F10_shGli1-2 cells were measured by quantitative RT-PCR as in Figure 1e,f. *P < 0.05; **P < 0.01;
***P < 0.001; n.s., not significant.
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sonicator (CosmoBio, Tokyo, Japan). The lysates were
immunoprecipitated with the rabbit anti-GLI1 H300 Ab (sc-
20687; Santa Cruz Biotechnology) or control rabbit IgG
(011-000-003; Jackson ImmunoResearch Laboratory, West
Grove, PA, USA), and the precipitated DNA was subjected
to quantitative PCR (qPCR). Primers used for the qPCR are
listed in Table S3.
Animal experiments. All experimental procedures involving
mice were approved by the Institutional Animal Care and Use
Committee of Kanazawa University. To evaluate the cells’
metastatic ability, in vivo metastasis assays were performed in
mice. B16F10 cells suspended in 200 lL of PBS containing
5% FBS were injected into the tail vein of 8-week-old male
C57BL/6 mice (Sankyo Labo Service, Tokyo, Japan). The
mice were sacrificed 14 days after the inoculation, and the
lungs were fixed in 10% formaldehyde. The metastatic foci in
the lungs were counted under a microscope to evaluate the
development of pulmonary metastasis.
Statistical analysis. Significance was determined using a two-
tailed unpaired Student’s t-test. Values of P < 0.05 were con-
sidered to be statistically significant.
Results
Blockade of Shh signaling inhibits the invasion ability of mela-
noma cells without affecting their MITF expression and activ-
ity. We first examined the role of Shh signaling in maintaining
the invasive phenotype of melanoma cells. We used the highly
metastatic murine melanoma cell line B16F10, which is widely
used as a model system to study melanoma biology, and
blocked the Shh-GLI signaling pathway using cyclopamine, an
inhibitor of SMO. B16F10 cells treated with cyclopamine at
relatively low concentrations, 2.5 and 5 lM, showed decreased
levels of GLI1 protein and of GLI-mediated transcriptional
activity, in a dose-dependent manner (Fig. 1a,b). We also
examined the expression of GLI2 and GLI3, which mainly
function as a transcriptional activator and repressor, respec-
tively. GLI2 was decreased by cyclopamine, but to a lesser
degree than GLI1 (Fig. 1b). The processed, repressive form of
GLI3 (GLI3-R) was slightly increased, and full-length GLI3
(GLI3-FL) was decreased, in cyclopamine-treated B16F10
cells in a dose-dependent manner (Fig. 1c). We then per-
formed an in vitro invasion assay. As shown in Figure 1d and
e, blocking Shh signaling with cyclopamine caused a dose-
dependent decrease in invasion activity, in which a statistically
significant difference was observed between cyclopamine-
untreated and cyclopamine-treated B16F10 cells at 5 lM, but
not 2.5 lM. There was no significant effect of cyclopamine at
either concentration on cell viability under the conditions used
for the invasion assay (Fig. S1).
The invasive phenotype of melanoma cells is often charac-
terized by low levels of MITF. Therefore, we examined the
protein levels of MITF by western blotting in cyclopamine-
treated B16F10 cells at 2.5 and 5 lM, and compared it to that
in cyclopamine-untreated cells. Unexpectedly, the MITF levels
were comparable among these cells (Fig. 1b). There were also
no significant differences in the mRNA levels of Mitf and
Tyrosinase (Tyr), a MITF-target gene, in these cells (Fig. 1f,
g). To rule out the possibility that the transcriptional regula-
tion of the Mitf gene was impaired in the B16F10 cells, we
stimulated the cells with forskolin, a cAMP-elevating reagent
known to induce Mitf promoter activity. As expected, the pro-
tein and mRNA levels of MITF and Tyr were increased,
respectively, in the forskolin-treated B16F10 cells (Fig. S2).
Taken together, these results indicated that blocking the Shh
signaling by cyclopamine inhibits the invasion ability of
B16F10 melanoma cells without affecting their MITF expres-
sion and activity.
Fig. 3. Gli1 knockdown (KD) decreases the lung
metastasis ability of B16F10 cells. (a) Representative
images of the lungs of mice injected with
B16F10_shLuc or B16F10_shGli1-1 cells. (b) Each
open circle denotes the number of nodules
representing the pulmonary metastasis ability of
B16F10_shLuc and B16F10_shGli1-1 cells in mice
treated as in (a). Data are the means  SEM (n = 15
mice per group). ***P < 0.001. Scale bar, 0.5 cm.
Fig. 4. Gli1 knockdown (KD) induces reversal of the mesenchymal-like phenotype. (a) B16F10_shLuc and B16F10_shGli1-1 cells, which express
enhanced green fluorescent protein (EGFP), were double stained with rhodamine-phalloidin and DAPI. Lower panels show higher-magnification
images of the boxed areas in the upper panels. (b) Relative mRNA levels of E-cadherin (Cdh1) in the B16F10_shLuc and B16F10_shGli1-1 cells
were measured by quantitative RT-PCR (qRT-PCR) as in Figure 1e,f. (c) The protein levels of E-cadherin in B16F10_shLuc and B16F10_shGli1-1 cells
were examined by western blotting using an anti-E-cadherin Ab. a-tubulin, a loading control. (d) B16F10_shLuc and B16F10_shGli1-1 cells were
double stained with DAPI and an anti-E-cadherin Ab. Lower panels show higher-magnification Z-stack images of the boxed areas in the upper
panels. Z-stack images were acquired using a confocal microscope as described in the Materials and Methods. (e) Relative mRNA levels of N-cad-
herin (Cdh2), vimentin (Vim) and fibronectin (Fn1) in B16F10_shLuc and B16F10_shGli1 cells were measured by qRT-PCR as in (b). *P < 0.05;
**P < 0.01. Scale bars, 100 lm.
© 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
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Fig. 5. GLI1 transcriptionally regulates the expression of Snail1, Zeb1 and Twist1. (a) Expression of epithelial-to-mesenchymal transition-indu-
cing transcription factors (EMT-TF) in Gli1 KD B16F10 cells. Relative mRNA levels of Snail1, Snail2, Zeb1, Zeb2 and Twist1 in B16F10_shLuc and
B16F10_shGli1-1 cells were measured by qRT-PCR as in Figure 1e,f. (b) Scheme of the potential promoter regions of Snail1, Zeb1 and Twist1, and
the Luc reporter. Numbers indicate the position relative to the transcriptional start sites (+1). Closed vertical boxes represent putative GLI-binding
sites. Core sequences of the GLI-binding motif are shown by uppercase letters, in which the underlined nucleotides differ from the consensus
sequences. Open and closed arrowheads indicate qPCR primers. (c–h) ChIP and quantitative PCR (c,e,g), and Luc (d,f,h) assays were performed as
described in the Materials and Methods. *P < 0.05; **P < 0.01; ***P < 0.001; n.s., not significant.
© 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
on behalf of Japanese Cancer Association.
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Gli1 knockdown inhibits the invasion ability and migration of
melanoma cells, independently of the regulation of MITF expres-
sion and activity. We next asked whether GLI1, a reliable mar-
ker for Shh pathway activity,(39,40) is responsible for the
invasive phenotype of melanoma cells. We established Gli1
KD B16F10 cells using two Gli1-targeting lentiviral shRNA
(shGli1-1 and shGli1-2) to exclude off-target effects (Fig. 2a),
and then examined the invasion ability and migration of the
Gli1 KD cells. The invasion ability of the KD cells was sub-
stantially reduced compared to that of control B16F10 cells
expressing a Luc-targeting lentiviral shRNA (shLuc; Fig. 2b,c).
No significant differences in viability were detected between
the shLuc-expressing and shGli1-expressing B16F10 cells
under the culture conditions used for the invasion assay
(Fig. S3a). In addition, overexpressing GLI1 in B16F10 cells
significantly increased the cells’ invasion activity (Fig. S4).
The cell migration activity, which was evaluated by an in vitro
wound-healing assay, was also inhibited by knocking down
Gli1 (Fig. 2d,e). We then analyzed the expression levels of
MITF (protein and mRNA) and its target gene Tyr in the Gli1
KD B16F10 cells, and found that the MITF and Tyr levels
were unchanged (Fig. 2a,f,g), as seen in the cyclopamine-trea-
ted B16F10 cells (Fig. 1b,f,g). Similar effects on the cell
migration and invasion abilities and the MITF expression and
activity were obtained using GLI1 KD MeWo (wild-type
BRAF/NRAS) and G361 (BRAFV600E) cells, which are meta-
static human melanoma cell lines (Fig. S5). Taken together,
these results strongly suggested that GLI1 plays a crucial role
in maintaining the invasive phenotype of melanoma cells,
independently of the regulation of MITF expression and activ-
ity.
Gli1 knockdown prevents the lung metastasis ability of B16F10
cells. The results of the in vitro invasion and migration assays
obtained with Gli1 KD melanoma cells (Figs 2 and S5)
prompted us to examine the metastatic ability of the KD cells
in vivo. We performed an experimental in vivo metastasis
assay, in which B16F10 cells expressing shLuc (control) or
shGli1 were injected into the mouse tail vein, and lung metas-
tasis was evaluated. There were many fewer metastatic nodules
in the lungs of mice injected with shGli1-expressing cells than
in the lungs of control B16F10-injected mice (Fig. 3), indicat-
ing that Gli1 KD decreases the lung metastasis ability of
B16F10 cells.
Gli1 knockdown induces a reversal of the mesenchymal-like
phenotype. During analysis, we noticed that the Gli1 KD
B16F10 cells tended to associate with each other, and that they
changed morphologically. Further examination by phalloidin
staining showed that stress fiber formation was severely inhib-
ited in the Gli1 KD cells (Fig. 4a). Consistent with the
changes in morphology and cytoskeletal structures, the expres-
sion levels of E-cadherin (protein and mRNA) were substan-
tially increased, with the E-cadherin protein being
predominantly localized to areas of cell–cell contact, in the
Gli1 KD cells (Fig. 4b–d). Furthermore, the mRNA expression
levels of mesenchymal markers, such as N-cadherin and
vimentin, were significantly decreased in the Gli1 KD cells
compared to the shLuc-expressing control cells (Fig. 4e). Simi-
lar expression profiles of E-cadherin and mesenchymal markers
were obtained using MeWo and G361 cells (Fig. S6). These
results may indicate that GLI1 regulates a subset of EMT-TF
to prevent the reverse transition from a mesenchymal-like to
an epithelial-like phenotype.
GLI1 transcriptionally regulates the expression of Snail1, Zeb1
and Twist1. We further investigated whether GLI1 modulates
the expression of key EMT-TF, including SNAIL and ZEB
family members. As shown in Figure 5a, the mRNA levels of
Snail1, Zeb1 and Twist1 were significantly decreased in the
Gli1 KD B16F10 cells compared to the control B16F10 cells,
whereas no significant differences in the Snail2 or Zeb2
mRNA levels were observed between the Gli1 KD and control
cells. Using the MatInspector software,(41) we identified several
putative GLI-binding sites within the 1-kb upstream region of
the transcriptional start sites of Snail1, Zeb1 and Twist1 (ter-
med S1 and S2 for Snail1; Z1, Z2 and Z3 for Zeb1; and T1,
T2 and T3 for Twist1; see Fig. 5b). We then conducted ChIP
assays with an anti-GLI1 Ab in B16F10 cells. The precipitated
DNA were analyzed by qPCR using primers specific for the
GLI1-binding sites (see Table S3 and Fig. S7). However,
because the regions around Z3 and T3, which are close to tran-
scriptional start sites, are GC-rich, we were unable to design
specific primer sets and, therefore, did not perform ChIP
experiments for them. The ChIP results revealed that GLI1
bound significantly to S1, Z1 and T1, but not to S2, Z2 or T2
(Fig. 5c,e,g). We then examined the effect of GLI1 overex-
pression on the potential promoters of Snail1, Zeb1 and Twist1
using reporter assays, and found that GLI1 overexpression sub-
stantially enhanced the promoter activities of the 1-kb regions.
The activities were not significantly increased when the
regions’ corresponding deletion derivatives were used (Fig. 5d,
f,h). Collectively, these results strongly suggest that GLI1
binds directly to the promoters of Snail1, Zeb1 and Twist1,
and regulates their expression. In addition, we found a signifi-
cant co-occurrence between GLI1 and ZEB1 (P = 0.002) and
between GLI1 and SNAIL1 (P = 0.004) by analyzing the
TCGA cutaneous melanoma dataset (287 samples with RNA
sequencing expression data) through the cBioPortal for cancer
genomic data.(42,43)
Discussion
Microphthalmia-associated transcription factor is a key mole-
cule that regulates heterogeneity in melanoma, and the so-
called MITF rheostat model has become widely accepted in
melanoma biology. In the present study, we demonstrated for
the first time that the transcription factor GLI1 plays an impor-
tant role in maintaining the invasive phenotype of melanoma
cells without affecting the MITF expression and activity. We
also showed that GLI1 prevents the reversal of the mesenchy-
mal-like phenotype of melanoma cells, most likely by modu-
lating a subset of EMT-TF. These findings provide new insight
into how a high degree of heterogeneity and plasticity is
achieved and regulated in melanoma.
Microenvironmental factors, such as hypoxia or TGF-b, are
known to influence both MITF expression and the phenotype
switching of melanoma cells.(17,20,44–47) In addition, Pierrat
et al.(44) report that Mitf is downregulated by GLI2 and TGF-b
to antagonize the MITF activity. Furthermore, Fai~ao-Flores
et al.(47) show that the GLI1 and GLI2 expressions increase
upon the acquisition of BRAF inhibitor (BRAFi) resistance in
melanoma cell lines and patient melanoma samples, where
again the inverse correlation between GLI1/2 and MITF
expression is observed. In contrast, in this study we found that
GLI1 exerts its function with little or no effect on the MITF
expression and activity. Nevertheless, the results of the present
study are not inconsistent with previous studies, considering
the following points. First, Gli1 is a direct transcriptional tar-
get of GLI2.(48,49) Second, GANT61, a pharmacological inhibi-
tor used in the previous studies, inhibits both the GLI1 and
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GLI2 activities.(50,51) Accordingly, as explained by Fai~ao-
Flores et al.(47) the increased expression of GLI2 by TGF-b
through a non-canonical Shh pathway results in an increase
and decrease in GLI1 and MITF expression, respectively,
which can be canceled by GANT61. Finally, although GLI1
and GLI2 have very similar consensus DNA-binding sites,(52)
GLI2, but not GLI1, may specifically regulate Mitf transcrip-
tion along with GLI2-interacting cofactors, which have been
proposed by Eichberger et al.(53) Taken together, it is conceiv-
able that GLI1 and GLI2 play distinct roles in the transcrip-
tional regulation of Mitf.
Recent studies have shown that a switch in the EMT-TF
expression pattern from SNAIL2high/ZEB2high/TWIST1low/
ZEB1low to SNAIL2low/ZEB2low/TWIST1high/ZEB1high occurs
during melanoma progression.(24,25) Caramel et al.(24) further
demonstrate that EMT-TF reprograming is associated with
decreased MITF expression and activity. In addition, Richard
et al.(54) report that ZEB1 plays a key role as a major driver
of melanoma cell plasticity and phenotypic resistance to
BRAFi, and that Zeb1 KD increases the sensitivity to BRAFi
in both MITFlow and MITFhigh cellular contexts. In this study,
in contrast, we found that Gli1 KD induced a mesenchymal–
epithelial-like transition in melanoma cells, which was accom-
panied by severely decreased invasive and migratory proper-
ties, and by an increased expression of E-cadherin and
downregulation of mesenchymal markers. We also observed
decreased mRNA levels of Snail1, Zeb1 and Twist1, but not of
Snail2 or Zeb2, in the Gli1 KD melanoma cells. It is reported
that SNAIL1 and TWIST1 cooperatively control Zeb1 expres-
sion during EMT in epithelial cells.(55) Taken together with
the results of our ChIP and Luc reporter assays (Fig. 5), it is
conceivable that GLI1 directly regulates the transcriptional
expression of a subset of EMT-TF, including Snail1 and
Twist1, as in non-melanoma cancer cells,(56,57) to maintain the
invasive activity of melanoma cells through MITF-independent
mechanisms. Further studies are needed to clarify this issue.
An increased expression of Gli1 has been observed in
BRAFi-resistant melanoma cells and patient samples,(47) as
well as during melanoma progression.(58) Taken together with
our present results, GLI1 may play a role in generating a high
level of intratumor heterogeneity in melanoma. Targeting
GLI1 may, therefore, be an effective approach for melanoma
therapy. Indeed, accumulating evidence suggests that GLI
antagonists, of which GANT61 has been most extensively
studied in vitro and in animal models, are promising therapeu-
tic candidates for a wide range of cancers, including mela-
noma.(59) However, GANT61 and other GLI antagonists, such
as arsenic trioxide,(59) inhibit the activity not only of GLI1,
but also of GLI2, which is a negative regulator of MITF
expression and function, as described above. MITF plays an
important, but complex role in melanoma biology, in which
MITF-low melanomas appear to be more invasive and MITF-
high melanomas more proliferative.(24,25) Our present findings
suggest that GLI1-specific inhibitors may be more beneficial
for cancer patients than GLI1/2 antagonists. Further studies are
needed to investigate and develop such therapeutics.
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